ProQR Therapeutics Rating Lowered to Hold at StockNews.com
PRQR Stock | USD 3.44 0.10 2.82% |
Slightly above 62% of ProQR Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding ProQR Therapeutics BV suggests that many traders are alarmed. ProQR Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in ProQR Therapeutics BV. Many technical investors use ProQR Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ProQR |
StockNews.com cut shares of ProQR Therapeutics from a buy rating to a hold rating in a research note published on Friday morning. Several other brokerages have also recently issued reports on PRQR. Chardan Capital reiterated a neutral rating and issued a 2.00 price objective on shares of ProQR Therapeutics in a
Read at thelincolnianonline.com
ProQR Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ProQR Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ProQR Therapeutics Fundamental Analysis
We analyze ProQR Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProQR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProQR Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
ProQR Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
ProQR Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ProQR Therapeutics stock to make a market-neutral strategy. Peer analysis of ProQR Therapeutics could also be used in its relative valuation, which is a method of valuing ProQR Therapeutics by comparing valuation metrics with similar companies.
Peers
ProQR Therapeutics Related Equities
ARWR | Arrowhead Pharmaceuticals | 12.03 | ||||
CTMX | CytomX Therapeutics | 6.25 | ||||
ANNX | Annexon | 3.73 | ||||
NUVB | Nuvation Bio | 3.21 | ||||
ASMB | Assembly Biosciences | 2.63 | ||||
APLS | Apellis Pharmaceuticals | 2.26 | ||||
TERN | Terns Pharmaceuticals | 1.55 | ||||
ACHL | Achilles Therapeutics | 0.94 | ||||
ALNY | Alnylam Pharmaceuticals | 0.94 | ||||
DAWN | Day One | 0.89 | ||||
BPMC | Blueprint Medicines | 0.81 | ||||
WVE | Wave Life | 0.40 | ||||
SPRO | Spero Therapeutics | 1.74 | ||||
NXTC | NextCure | 2.50 | ||||
TIL | Instil Bio | 2.83 |
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.